November 18, 2021
Chugai Pharmaceutical said on November 16 that it has received an additional indication for its FoundationOne CDx Cancer Genomic Profile to identify advanced/recurrent tumor mutation burden-high (TMB-High) solid tumors. With this approval, the product will be used as a companion...read more